# A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

> **NCT06594991** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 88 (estimated)

## Conditions studied

- Advanced Melanoma

## Interventions

- **DRUG:** Fianlimab
- **DRUG:** Cemiplimab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT06594991
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06594991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06594991, "A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT06594991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*